June FDA Actions in brief

Patient autonomy needs to be balanced with an obligation to educate patients about the risk and benefits of the complementary and alternative medicine treatments, say the authors of an article in the Journal of the American Academy of Dermatology.

In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.

Dario is using Sanofi’s research infrastructure to evaluate its digital health products.

The US accounted for nearly half of the atopic dermatitis drugs market in 2021. According to 2021 data from the National Center for Health Statistics, roughly 7% of adults in the U.S. have eczema.